This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Bionano (BNGO) will provide updates on its revenues and earnings when it reports fourth-quarter and full-year 2020 results.
Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) will provide updates on its pipeline when it reports fourth-quarter 2020 results.
Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.
What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?
by Zacks Equity Research
Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.
Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences
by Zacks Equity Research
Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences
5 Stocks Set to Pop on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Biosciences (CSTL).
Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.
Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.
Zacks.com featured highlights include: Daqo, Surface Oncology, Covenant, Herc and Castle Biosciences
by Zacks Equity Research
Zacks.com featured highlights include: Daqo, Surface Oncology, Covenant, Herc and Castle Biosciences
Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis
by Zacks Equity Research
Regeneron (REGN) gets positive CHMP opinion for Dupixent, recommending extending the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis.
Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study
by Zacks Equity Research
Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.
Precigen (PGEN) Looks Good: Stock Adds 7.1% in Session
by Zacks Equity Research
Precigen (PGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
AnaptysBio Shares Up on Positive Top-Line Psoriasis Data
by Zacks Equity Research
AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.
Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma
by Zacks Equity Research
Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.
Alexion's Ultomiris Gets FDA Approval for New Formulation
by Zacks Equity Research
Alexion (ALXN) gets FDA approval for Ultomiris 100 mg/mL, a new advanced formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 80.95% and 39.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Castle Biosciences.
How Castle Biosciences (CSTL) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Castle Biosciences (CSTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Castle Biosciences, Inc. (CSTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Castle Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) has been struggling lately, but the selling pressure may be coming to an end soon.
Castle Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Castle Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.